hydroxychloroquine - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.35 [0.43, 4.19]< 10%4 studies (4/-)30.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.51 [0.07, 3.68]< 10%1 study (1/-)74.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.36 [0.87, 2.11]> 10%1 study (1/-)91.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.36 [0.87, 2.11]> 10%1 study (1/-)91.0 %some concernnot evaluable moderateimportant-
hospitalization 0.77 [0.55, 1.10]< 10%3 studies (3/-)92.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 1.32 [0.46, 3.79]< 10%1 study (1/-)30.3 %some concernnot evaluable moderateimportant-
ICU admission 0.84 [0.43, 1.63]< 10%1 study (1/-)69.8 %some concernnot evaluable moderatenon important-

safety endpoints 00

adverse events 21.73 [0.36, 1295.07]< 199%2 studies (2/-)7.4 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.